Analysed PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) News Sources
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
09-04-2026
yahoo.com
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
13-04-2026
yahoo.com
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
07-05-2026
yahoo.com
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
12-05-2026
yahoo.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
18-06-2026
yahoo.com
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
25-06-2026
yahoo.com
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
26-06-2026
yahoo.com
What is the current price of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The current price of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is $1.02.
PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) since the previous trading day is $-0.02.
PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) since the previous trading day is -1.9231%.
What is the most recent average sentiment score for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The most recent average sentiment score for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The most recent sentiment for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is .
SEC-8K** Filing Available For PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.